Triple-Drug cocktail aims to tame untreated CLL
NCT ID NCT07674810
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—can safely control chronic lymphocytic leukemia (CLL) in people who have not yet received treatment. About 40 participants will receive all three drugs orally. The main goal is to check for side effects and see how well the body tolerates the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib, sonrotoclax, and obinutuzumab
What this could lead to
If successful, this three-drug combination could offer a powerful new option to control CLL without prior treatment, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial (40 people) focused on safety. The combination may cause side effects, and it is not yet known if it works better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact